ID   CP7B1_HUMAN             Reviewed;         506 AA.
AC   O75881; B2RN07; Q9UNF5;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   11-FEB-2002, sequence version 2.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=25-hydroxycholesterol 7-alpha-hydroxylase;
DE            EC=1.14.14.29 {ECO:0000269|PubMed:10588945};
DE   AltName: Full=Cytochrome P450 7B1;
DE   AltName: Full=Oxysterol 7-alpha-hydroxylase;
GN   Name=CYP7B1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INVOLVEMENT IN CBAS3, AND VARIANT HIS-324.
RC   TISSUE=Liver, and Spleen;
RX   PubMed=9802883; DOI=10.1172/JCI2962;
RA   Setchell K.D.R., Schwarz M., O'Connell N.C., Lund E.G., Davis D.L.,
RA   Lathe R., Thompson H.R., Tyson W.R., Sokol R.J., Russell D.W.;
RT   "Identification of a new inborn error in bile acid synthesis: mutation
RT   of the oxysterol 7-alpha-hydroxylase gene causes severe neonatal liver
RT   disease.";
RL   J. Clin. Invest. 102:1690-1703(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, AND CATALYTIC
RP   ACTIVITY.
RC   TISSUE=Hippocampus;
RX   PubMed=10588945;
RA   Wu Z.L., Martin K.O., Javitt N.B., Chiang J.Y.L.;
RT   "Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs
RT   and gene CYP7B1.";
RL   J. Lipid Res. 40:2195-2203(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [6]
RP   VARIANTS SPG5A ARG-57; SER-216; PHE-363 AND HIS-417.
RX   PubMed=18252231; DOI=10.1016/j.ajhg.2007.10.001;
RA   Tsaousidou M.K., Ouahchi K., Warner T.T., Yang Y., Simpson M.A.,
RA   Laing N.G., Wilkinson P.A., Madrid R.E., Patel H., Hentati F.,
RA   Patton M.A., Hentati A., Lamont P.J., Siddique T., Crosby A.H.;
RT   "Sequence alterations within CYP7B1 implicate defective cholesterol
RT   homeostasis in motor-neuron degeneration.";
RL   Am. J. Hum. Genet. 82:510-515(2008).
RN   [7]
RP   VARIANTS SPG5A ALA-297; CYS-417; HIS-417; ILE-470 AND CYS-486, AND
RP   VARIANTS PRO-19; TYR-106; SER-287 AND HIS-324.
RX   PubMed=19439420; DOI=10.1093/brain/awp073;
RA   Goizet C., Boukhris A., Durr A., Beetz C., Truchetto J., Tesson C.,
RA   Tsaousidou M., Forlani S., Guyant-Marechal L., Fontaine B.,
RA   Guimaraes J., Isidor B., Chazouilleres O., Wendum D., Grid D.,
RA   Chevy F., Chinnery P.F., Coutinho P., Azulay J.P., Feki I., Mochel F.,
RA   Wolf C., Mhiri C., Crosby A., Brice A., Stevanin G.;
RT   "CYP7B1 mutations in pure and complex forms of hereditary spastic
RT   paraplegia type 5.";
RL   Brain 132:1589-1600(2009).
RN   [8]
RP   VARIANTS SPG5A VAL-87; LEU-285; ALA-297 AND ALA-443.
RX   PubMed=21214876; DOI=10.1111/j.1399-0004.2011.01624.x;
RA   Arnoldi A., Crimella C., Tenderini E., Martinuzzi A., D'Angelo M.G.,
RA   Musumeci O., Toscano A., Scarlato M., Fantin M., Bresolin N.,
RA   Bassi M.T.;
RT   "Clinical phenotype variability in patients with hereditary spastic
RT   paraplegia type 5 associated with CYP7B1 mutations.";
RL   Clin. Genet. 81:150-157(2012).
RN   [9]
RP   VARIANTS SPG5A ASP-147; ALA-316 INS AND CYS-486.
RX   PubMed=24117163; DOI=10.1111/ane.12188;
RA   Roos P., Svenstrup K., Danielsen E.R., Thomsen C., Nielsen J.E.;
RT   "CYP7B1: novel mutations and magnetic resonance spectroscopy
RT   abnormalities in hereditary spastic paraplegia type 5A.";
RL   Acta Neurol. Scand. 129:330-334(2014).
RN   [10]
RP   VARIANT SPG5A CYS-486.
RX   PubMed=27217339; DOI=10.1093/brain/aww111;
RA   Kara E., Tucci A., Manzoni C., Lynch D.S., Elpidorou M.,
RA   Bettencourt C., Chelban V., Manole A., Hamed S.A., Haridy N.A.,
RA   Federoff M., Preza E., Hughes D., Pittman A., Jaunmuktane Z.,
RA   Brandner S., Xiromerisiou G., Wiethoff S., Schottlaender L.,
RA   Proukakis C., Morris H., Warner T., Bhatia K.P., Korlipara L.V.,
RA   Singleton A.B., Hardy J., Wood N.W., Lewis P.A., Houlden H.;
RT   "Genetic and phenotypic characterization of complex hereditary spastic
RT   paraplegia.";
RL   Brain 139:1904-1918(2016).
RN   [11]
RP   VARIANT SPG5A ARG-198, AND VARIANT HIS-324.
RX   PubMed=26714052; DOI=10.1016/j.mcp.2015.12.001;
RA   Schubert S.F., Hoffjan S., Dekomien G.;
RT   "Mutational analysis of the CYP7B1, PNPLA6 and C19orf12 genes in
RT   autosomal recessive hereditary spastic paraplegia.";
RL   Mol. Cell. Probes 30:53-55(2016).
CC   -!- FUNCTION: Oxysterol 7alpha-hydroxylase that mediates formation of
CC       7-alpha,25-dihydroxycholesterol (7-alpha,25-OHC) from 25-
CC       hydroxycholesterol (PubMed:10588945). Plays a key role in cell
CC       positioning and movement in lymphoid tissues: 7-alpha,25-
CC       dihydroxycholesterol (7-alpha,25-OHC) acts as a ligand for the G
CC       protein-coupled receptor GPR183/EBI2, a chemotactic receptor for a
CC       number of lymphoid cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q60991, ECO:0000269|PubMed:10588945}.
CC   -!- CATALYTIC ACTIVITY: Cholest-5-ene-3-beta,25-diol + [reduced
CC       NADPH--hemoprotein reductase] + O(2) = cholest-5-ene-3-beta,7-
CC       alpha,25-triol + [oxidized NADPH--hemoprotein reductase] + H(2)O.
CC       {ECO:0000269|PubMed:10588945}.
CC   -!- CATALYTIC ACTIVITY: (25R)-cholest-5-ene-3-beta,26-diol + [reduced
CC       NADPH--hemoprotein reductase] + O(2) = (25R)-cholest-5-ene-3-
CC       beta,7-alpha,26-triol + [oxidized NADPH--hemoprotein reductase] +
CC       H(2)O. {ECO:0000269|PubMed:10588945}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413; Evidence={ECO:0000250};
CC   -!- PATHWAY: Lipid metabolism; bile acid biosynthesis.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC   -!- TISSUE SPECIFICITY: Brain, testis, ovary, prostate, liver, colon,
CC       kidney, and small intestine.
CC   -!- DISEASE: Spastic paraplegia 5A, autosomal recessive (SPG5A)
CC       [MIM:270800]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. {ECO:0000269|PubMed:18252231,
CC       ECO:0000269|PubMed:19439420, ECO:0000269|PubMed:21214876,
CC       ECO:0000269|PubMed:24117163, ECO:0000269|PubMed:26714052,
CC       ECO:0000269|PubMed:27217339}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Congenital bile acid synthesis defect 3 (CBAS3)
CC       [MIM:613812]: A disorder resulting in severe cholestasis,
CC       cirrhosis and liver synthetic failure. Hepatic microsomal
CC       oxysterol 7-alpha-hydroxylase activity is undetectable.
CC       {ECO:0000269|PubMed:9802883}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CYP7B1ID40255ch8q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF029403; AAC95426.1; -; mRNA.
DR   EMBL; AF127090; AAD20021.1; -; mRNA.
DR   EMBL; AF176805; AAK11850.1; -; Genomic_DNA.
DR   EMBL; AF176800; AAK11850.1; JOINED; Genomic_DNA.
DR   EMBL; AF176801; AAK11850.1; JOINED; Genomic_DNA.
DR   EMBL; AF176802; AAK11850.1; JOINED; Genomic_DNA.
DR   EMBL; AF176803; AAK11850.1; JOINED; Genomic_DNA.
DR   EMBL; AF176804; AAK11850.1; JOINED; Genomic_DNA.
DR   EMBL; CH471068; EAW86877.1; -; Genomic_DNA.
DR   EMBL; BC136574; AAI36575.1; -; mRNA.
DR   CCDS; CCDS6180.1; -.
DR   RefSeq; NP_004811.1; NM_004820.4.
DR   UniGene; Hs.657330; -.
DR   UniGene; Hs.667720; -.
DR   ProteinModelPortal; O75881; -.
DR   SMR; O75881; -.
DR   BioGrid; 114813; 2.
DR   STRING; 9606.ENSP00000310721; -.
DR   SwissLipids; SLP:000001207; -.
DR   iPTMnet; O75881; -.
DR   PhosphoSitePlus; O75881; -.
DR   BioMuta; CYP7B1; -.
DR   MaxQB; O75881; -.
DR   PaxDb; O75881; -.
DR   PeptideAtlas; O75881; -.
DR   PRIDE; O75881; -.
DR   Ensembl; ENST00000310193; ENSP00000310721; ENSG00000172817.
DR   GeneID; 9420; -.
DR   KEGG; hsa:9420; -.
DR   UCSC; uc003xvj.3; human.
DR   CTD; 9420; -.
DR   DisGeNET; 9420; -.
DR   GeneCards; CYP7B1; -.
DR   HGNC; HGNC:2652; CYP7B1.
DR   HPA; HPA017761; -.
DR   MalaCards; CYP7B1; -.
DR   MIM; 270800; phenotype.
DR   MIM; 603711; gene.
DR   MIM; 613812; phenotype.
DR   neXtProt; NX_O75881; -.
DR   OpenTargets; ENSG00000172817; -.
DR   Orphanet; 100986; Autosomal recessive spastic paraplegia type 5A.
DR   Orphanet; 79302; Congenital bile acid synthesis defect type 3.
DR   PharmGKB; PA27124; -.
DR   eggNOG; KOG0684; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00550000074551; -.
DR   HOGENOM; HOG000231026; -.
DR   HOVERGEN; HBG051100; -.
DR   InParanoid; O75881; -.
DR   KO; K07430; -.
DR   OMA; REKIIKC; -.
DR   OrthoDB; EOG091G07UI; -.
DR   PhylomeDB; O75881; -.
DR   TreeFam; TF105090; -.
DR   BRENDA; 1.14.13.100; 2681.
DR   Reactome; R-HSA-192105; Synthesis of bile acids and bile salts.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   UniPathway; UPA00221; -.
DR   GeneWiki; CYP7B1; -.
DR   GenomeRNAi; 9420; -.
DR   PRO; PR:O75881; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000172817; -.
DR   CleanEx; HS_CYP7B1; -.
DR   Genevisible; O75881; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0008396; F:oxysterol 7-alpha-hydroxylase activity; ISS:UniProtKB.
DR   GO; GO:0035754; P:B cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0006699; P:bile acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR024204; Cyt_P450_CYP7A1-type.
DR   InterPro; IPR002403; Cyt_P450_E_grp-IV.
DR   Pfam; PF00067; p450; 1.
DR   PIRSF; PIRSF000047; Cytochrome_CYPVIIA1; 1.
DR   PRINTS; PR00465; EP450IV.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
PE   1: Evidence at protein level;
KW   Cholesterol metabolism; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Heme; Hereditary spastic paraplegia;
KW   Intrahepatic cholestasis; Iron; Lipid metabolism; Membrane;
KW   Metal-binding; Microsome; Monooxygenase; NADP; Neurodegeneration;
KW   Oxidoreductase; Polymorphism; Reference proteome; Steroid metabolism;
KW   Sterol metabolism.
FT   CHAIN         1    506       25-hydroxycholesterol 7-alpha-
FT                                hydroxylase.
FT                                /FTId=PRO_0000051906.
FT   METAL       449    449       Iron (heme axial ligand). {ECO:0000250}.
FT   VARIANT      19     19       L -> P (in dbSNP:rs72554624).
FT                                {ECO:0000269|PubMed:19439420}.
FT                                /FTId=VAR_075505.
FT   VARIANT      57     57       G -> R (in SPG5A; dbSNP:rs121908614).
FT                                {ECO:0000269|PubMed:18252231}.
FT                                /FTId=VAR_044382.
FT   VARIANT      87     87       G -> V (in SPG5A; dbSNP:rs587777221).
FT                                {ECO:0000269|PubMed:21214876}.
FT                                /FTId=VAR_075506.
FT   VARIANT     106    106       H -> Y. {ECO:0000269|PubMed:19439420}.
FT                                /FTId=VAR_075507.
FT   VARIANT     147    147       G -> D (in SPG5A; unknown pathological
FT                                significance; dbSNP:rs754730601).
FT                                {ECO:0000269|PubMed:24117163}.
FT                                /FTId=VAR_075508.
FT   VARIANT     198    198       G -> R (in SPG5A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26714052}.
FT                                /FTId=VAR_075509.
FT   VARIANT     216    216       F -> S (in SPG5A; dbSNP:rs121908612).
FT                                {ECO:0000269|PubMed:18252231}.
FT                                /FTId=VAR_044383.
FT   VARIANT     285    285       H -> L (in SPG5A; dbSNP:rs750781606).
FT                                {ECO:0000269|PubMed:21214876}.
FT                                /FTId=VAR_075510.
FT   VARIANT     287    287       L -> S. {ECO:0000269|PubMed:19439420}.
FT                                /FTId=VAR_075511.
FT   VARIANT     297    297       T -> A (in SPG5A; dbSNP:rs587777222).
FT                                {ECO:0000269|PubMed:19439420,
FT                                ECO:0000269|PubMed:21214876}.
FT                                /FTId=VAR_075512.
FT   VARIANT     316    316       A -> AA (in SPG5A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24117163}.
FT                                /FTId=VAR_075513.
FT   VARIANT     324    324       R -> H (in dbSNP:rs59035258).
FT                                {ECO:0000269|PubMed:19439420,
FT                                ECO:0000269|PubMed:26714052}.
FT                                /FTId=VAR_075514.
FT   VARIANT     363    363       S -> F (in SPG5A; dbSNP:rs121908610).
FT                                {ECO:0000269|PubMed:18252231}.
FT                                /FTId=VAR_044384.
FT   VARIANT     417    417       R -> C (in SPG5A; dbSNP:rs367916692).
FT                                {ECO:0000269|PubMed:19439420}.
FT                                /FTId=VAR_075515.
FT   VARIANT     417    417       R -> H (in SPG5A; dbSNP:rs121908611).
FT                                {ECO:0000269|PubMed:18252231,
FT                                ECO:0000269|PubMed:19439420}.
FT                                /FTId=VAR_044385.
FT   VARIANT     443    443       G -> A (in SPG5A).
FT                                {ECO:0000269|PubMed:21214876}.
FT                                /FTId=VAR_075516.
FT   VARIANT     470    470       F -> I (in SPG5A; dbSNP:rs267606758).
FT                                {ECO:0000269|PubMed:19439420}.
FT                                /FTId=VAR_075517.
FT   VARIANT     486    486       R -> C (in SPG5A; dbSNP:rs116171274).
FT                                {ECO:0000269|PubMed:19439420,
FT                                ECO:0000269|PubMed:24117163,
FT                                ECO:0000269|PubMed:27217339}.
FT                                /FTId=VAR_075518.
SQ   SEQUENCE   506 AA;  58256 MW;  07D3D4B801B6DBD9 CRC64;
     MAGEVSAATG RFSLERLGLP GLALAAALLL LALCLLVRRT RRPGEPPLIK GWLPYLGVVL
     NLRKDPLRFM KTLQKQHGDT FTVLLGGKYI TFILDPFQYQ LVIKNHKQLS FRVFSNKLLE
     KAFSISQLQK NHDMNDELHL CYQFLQGKSL DILLESMMQN LKQVFEPQLL KTTSWDTAEL
     YPFCSSIIFE ITFTTIYGKV IVCDNNKFIS ELRDDFLKFD DKFAYLVSNI PIELLGNVKS
     IREKIIKCFS SEKLAKMQGW SEVFQSRQDV LEKYYVHEDL EIGAHHLGFL WASVANTIPT
     MFWAMYYLLR HPEAMAAVRD EIDRLLQSTG QKKGSGFPIH LTREQLDSLI CLESSIFEAL
     RLSSYSTTIR FVEEDLTLSS ETGDYCVRKG DLVAIFPPVL HGDPEIFEAP EEFRYDRFIE
     DGKKKTTFFK RGKKLKCYLM PFGTGTSKCP GRFFALMEIK QLLVILLTYF DLEIIDDKPI
     GLNYSRLLFG IQYPDSDVLF RYKVKS
//
